NEW YORK (GenomeWeb News) — Cambridge BioScience today said it will distribute and support Chan Test’s potassium channel assays in Europe.

 

Cleveland-based Chan Test’s assay, based on ion channels, is designed to predict cardiac events associated with non-cardiac drugs.

 

Cambridge BioScience Managing Director Mike Kerns said his company expects “significant growth” for the assay due to “the rapidly growing interest in ion channels as primary targets in areas such as pain and epilepsy research.”